Exposure to metal ions regulates mRNA levels of APP and BACE1 in PC12 cells: Blockage by curcumin

Lin, Raozhou; Chen, Xiaohong; Li, Wenming; Han, Yifan; Liu, Peiqing; Pi, Rongbiao

doi:10.1016/j.neulet.2008.05.070

Cited by 104 publications

(71 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Curcumin is reported to suppress Aβ-induced β-site APP-cleaving enzyme 1 (BACE-1) upregulation at a concentration of 3-30 μM and curcumin depreciates the production of Aβ-induced reactive oxygen species at 1-30 μM concentration whereas 20 μM cucumin halted the structural changes in Aβ towards βsheet-rich secondary structure [62]. Another group of researcher showed that curcumin with concentration about 20 μM depreciated the over expression of APP and BACE-1 mRNA levels, which was increasing when treated with copper or manganese ions (50-100 μM) in a time and concentration dependent pattern [63] .…”

Section: Inhibition Of β-Secretase and Acetylcholinesterase Activitymentioning

confidence: 99%

Role of Curcumin in Treatment of Alzheimer Disease

Mukhopadhyay¹,

Ruidas²,

Chaudhury³

2017

Int J Neurorehabilitation Eng

View full text Add to dashboard Cite

A lot of research findings support that curcumin (diferuloyl methane) has antioxidant, anti-inflammatory and antitumor activity. In India, curcumin has a widespread use as food additive and herbal medicine for human diseases without any side effect. Though curcumin is well established as an anticancer agent but there are a few reports about its promising role against amyloid diseases. According to recent finding curcumin play a crucial inhibitory role in pathophysiology of Alzheimer's disease (AD). Oral administration of curcumin or its metabolites has shown the inhibition of Aβ deposition, Aβ oligomerization and tau phosphorylation in the brain of AD animal model including behavioural improvement. But still it is unknown whether the curcumin is directly involved in those processes or enhance those mechanisms. Thus in this review we want to focus on overall mechanism of curcumin in AD. Some strategies to overcome the problem of low absorption and fast clearance of curcumin nanoparticles have also been proposed.

show abstract

Section: Inhibition Of β-Secretase and Acetylcholinesterase Activitymentioning

confidence: 99%

Role of Curcumin in Treatment of Alzheimer Disease

Mukhopadhyay¹,

Ruidas²,

Chaudhury³

2017

Int J Neurorehabilitation Eng

View full text Add to dashboard Cite

show abstract

“…It was found that curcumin is capable of not only interfering with Aβ aggregation which leads to formation of Aβ fi brils, but also destabilizing preformed Aβ fi brils (77). In addition, it was reported that curcumin suppressed the up-regulation of APP and β-secretase mRNA levels caused by copper or manganese ions in a time-and dose-dependent manner (78 (81). Fourth, curcumin inhibits acetylcholinesterase activity.…”

Section: Curcuminmentioning

confidence: 99%

Research progress on natural products from traditional Chinese medicine in treatment of Alzheimer's disease

Gao

Inagaki

et al. 2013

Drug Discov Ther

View full text Add to dashboard Cite

Alzheimer's disease (AD) is a severe condition in aging societies. Although research on this disease is advancing rapidly, thus far few very effective drugs are available for AD patients. The currently widely used medicines such as donepezil and galantamine transiently improve the symptoms of patients with mild to moderate AD. They are hardly capable of preventing, halting or reversing the progression of this disease. In the long history of development of traditional Chinese medicine, many herbs have been discovered and employed to treat dementia diseases in clinics in China. In recent decades, a number of agents were isolated from these herbs and their efficacies against AD were tested. Some flavonoids, alkaloids, phenylpropanoids, triterpenoid saponins, and polysaccharides were demonstrated to have potential efficacies against AD via targeting multiple pathological changes of this disease. In this article, we reviewed research progress on the efficacies and underlying mechanisms of these agents.

show abstract

“…Early studies from this group (Liu et al, 2005) showed that these nanochelators can effectively remove iron from tissue of AD brain and also from ferritin. Some studies , Lin et al, 2008 recently demonstrated the potential application of curcumin, a commonly used spice extracted by turmeric, as an antiinflammatory and anti-oxidant molecule with neuroprotective properties. Some authors (Cole et al, 2007) demonstrated its metal chelating and neuroprotectant (Jiao et al, 2006) effects.…”

Section: Treatment Of Ad With Metal Complexing Agentsmentioning

confidence: 99%

“…Some authors (Cole et al, 2007) demonstrated its metal chelating and neuroprotectant (Jiao et al, 2006) effects. In particular, Lin and coworkers (Lin et al, 2008) demonstrated in PC12 cells that this compound has strong effects on APP and BACE1 transcription up-regulation mediated by copper. The authors suggest that curcumin might have a combined effect on suppressing APP and BACE1 transcriptions, blocking the effect of copper.…”

Section: Treatment Of Ad With Metal Complexing Agentsmentioning

confidence: 99%

“…The concept that copper content can modulate BACE1, i.e. the rate-limiting enzyme in the production of A (Angeletti et al, 2005), is supported by the recent evidence that copper (Cu 2+ ) and manganese (Mn 2+ ) potently increase the expression of both APP and BACE1 in a time-and concentration-dependent manner, whereas zinc (Zn 2+ ), iron (Fe 2+ ) and aluminum (Al 3+ ) do not (Lin et al, 2008). In vitro studies have demonstrated that different variants of A (1-40, 1-42) have different affinity for copper, and that higher affinity generates higher toxicity .…”

mentioning

confidence: 98%

See 1 more Smart Citation